Xylazine ("Tranq"): Effects, Risks & Treatment

Xylazine itself has no established DSM-5-TR substance use disorder category, but repeated exposure produces tolerance, and the clinically diagnosable condition is opioid use disorder because xylazine is almost always encountered mixed into fentanyl. Unlike alcohol, opioids, or sedatives, xylazine lacks a dedicated diagnostic entry in the DSM-5-TR, the diagnostic manual the American Psychiatric Association publishes. People who use xylazine-adulterated fentanyl typically meet criteria for opioid use disorder under the DSM-5-TR's 11-criterion framework, spanning impaired control, social impairment, risky use, tolerance, and withdrawal.

Tolerance to xylazine's sedative effect develops alongside opioid tolerance, requiring larger or more frequent doses of the combined product to achieve the same effect. The diagnostic ambiguity carries clinical weight: treatment must address the opioid use disorder driving compulsive use while separately managing xylazine-specific medical complications the drug produces on its own. Those complications surface first as observable signs and symptoms of xylazine exposure.

Xylazine exposure signs span behavioral, physical, and psychological domains, with heavy sedation beyond typical opioid effect and severe skin wounds forming the clearest clinical markers. Behavioral signs include using xylazine-adulterated fentanyl or heroin, seeking the drug despite worsening wounds, and needing help from others to stay awake or upright in public.

Physical signs include heavy, prolonged sedation that outlasts what opioids alone would cause, slurred speech, unresponsiveness, and severe, necrotic skin wounds and ulcers that can appear even at body sites with no history of injection. Track marks show abnormal, delayed healing distinct from typical injection-site trauma. Psychological signs include continued use despite visible tissue damage and denial of wound severity, a pattern that delays medical care. These physical markers carry direct consequences for acute overdose risk and long-term tissue damage.

Xylazine produces profound sedation, severe hypotension, bradycardia, and hypothermia that add to the respiratory depression fentanyl causes, creating a drug overdose risk pattern that resembles opioid overdose but resists opioid reversal. These acute effects stem from xylazine's action on alpha-2 adrenergic receptors rather than opioid receptors, so the sedation and cardiovascular depression it causes do not respond to opioid antagonists.

Naloxone does not reverse xylazine's sedative effects because xylazine does not act on opioid receptors, but naloxone must still be administered immediately in any suspected overdose because fentanyl or another opioid is almost always present in the mixture. Reversing the opioid component can be life-saving even when sedation from xylazine persists afterward. A pharmacokinetic mismatch makes that lingering sedation especially dangerous: xylazine's blood half-life runs only about 23 to 50 minutes and its clinical sedation commonly lasts 8 hours or more, yet the clinical sedation it produces stretches on for hours. That gap is why repeat naloxone dosing fails to wake the person and why responders must add rescue breathing and place the person in the recovery position until the sedation lifts. Chronic, cumulative xylazine exposure compounds this acute risk with necrotic skin wounds that progress to infection, abscess formation, and, in severe cases, amputation. The unpredictable severity of these combined effects carries directly into what withdrawal from xylazine-adulterated fentanyl looks like.

Xylazine-associated wounds are a distinct injury type driven by alpha-2-mediated vasoconstriction and reduced tissue oxygenation, not simple injection trauma, so ulcers can appear far from any injection site and progress to full-thickness necrosis. By constricting peripheral blood vessels wherever it circulates, xylazine starves skin and soft tissue of oxygen, so lesions surface on the legs, arms, and trunk regardless of where the drug entered the body.

Left untreated, these full-thickness wounds expose tendon and bone, become chronically infected, and force surgical debridement or amputation. The pattern is severe and consistent enough that Philadelphia clinicians published a surgical-management consensus and dedicated wound-care protocols to standardize treatment. Because the wounds keep worsening while use continues, clinicians treat them alongside the underlying dependence rather than waiting for abstinence, which is why testing and honest supply awareness matter for anyone still using.

Xylazine test strips detect xylazine in a drug sample, but standard fentanyl test strips do not, because the two strips screen for different compounds using different antibodies. Manufacturer BTNX produces dedicated xylazine test strips, separate from its widely distributed fentanyl strips; a person dissolves a small amount of the drug in water, dips the strip, and reads a result within minutes.

The strips carry real limits. They confirm whether xylazine is present, not how much is in the sample or how potent the batch is, and uneven mixing means a negative result on one portion does not guarantee the rest is xylazine-free. Neither a fentanyl strip nor a xylazine strip detects medetomidine, the newer adulterant now entering the supply. Harm-reduction programs distribute both strip types at low cost, but testing is a risk-reduction step, not a safety guarantee — and the supply the strips are chasing keeps shifting.

Medetomidine is an even more potent veterinary alpha-2 adrenergic agonist now appearing in the illicit fentanyl supply as a successor to xylazine, and it produces the same non-opioid sedation that naloxone cannot reverse. Sometimes called rhino tranq on the street, medetomidine deepens and prolongs sedation beyond what xylazine causes, and the CDC issued a national health advisory in April 2026 as its involvement in the drug supply climbed.

Xylazine has circulated in the fentanyl supply since roughly 2016 and is now widespread. In 2022 the DEA reported finding xylazine in about 23% of the fentanyl powder and 7% of the fentanyl pills it seized, and it seized fentanyl-xylazine mixtures in 48 of 50 states. The mixture travels under names including tranq, tranq dope, Philly dope, and sleep-cut, and the media nickname zombie drug reflects the hunched posture, prolonged unresponsiveness, and open wounds that heavy use produces. This shifting, unpredictable supply is exactly why treatment cannot target a single drug in isolation.

No FDA-approved medication treats xylazine dependence directly, so opioid addiction treatment centers on evidence-based care for the underlying opioid use disorder combined with medical monitoring and dedicated wound care. Buprenorphine or methadone medication-assisted treatment addresses the opioid dependence driving use, while clinicians monitor for the unpredictable, poorly characterized xylazine withdrawal pattern that can accompany opioid withdrawal.

Treatment begins with a medical assessment using the ASAM Criteria alongside wound and vital-sign screening. Because Ascend Recovery is an outpatient provider, medically monitored withdrawal is coordinated through detox placement that addresses the opioid and xylazine components together before clients step down into outpatient care. Necrotic skin injuries receive dedicated wound care alongside detox rather than after it, since untreated tissue damage risks infection and amputation. Clients then move into a partial hospitalization program (PHP) and intensive outpatient program (IOP), combining medication-assisted treatment with behavioral therapy for sustained recovery. Accessing this pathway starts with reaching a licensed provider near Palm Beach Gardens, Florida.

Xylazine withdrawal is not well-characterized in clinical research, unlike opioid or benzodiazepine withdrawal, which have established symptom timelines documented in the medical literature. No validated withdrawal scale or defined symptom duration exists for xylazine specifically, and the clinical literature has not established a fixed timeline.

Clinicians report a distinct syndrome that overlaps with opioid withdrawal but is described as more severe, including severe anxiety, restlessness, and pain that are not relieved by opioids or naloxone and that fail to fully respond to standard opioid withdrawal medications. That gap complicates buprenorphine induction, because relieving the opioid component does not settle the xylazine-driven agitation underneath it. Because xylazine is almost never used alone, withdrawal management must address the opioid and xylazine components simultaneously under medical supervision. Self-managed cessation carries danger given this unpredictability, which is why medically supervised care is the foundation of how xylazine addiction is treated.

Help for xylazine addiction starts with a confidential clinical assessment, not self-directed withdrawal, given the unpredictable severity of combined opioid-xylazine withdrawal. Attempting to stop use without medical supervision carries real danger because the xylazine withdrawal pattern is not well-characterized and can compound standard opioid withdrawal.

Ascend Recovery Center is a Joint Commission-accredited, Florida DCF-licensed outpatient behavioral health provider in Palm Beach Gardens serving South Florida clients. The clinical team coordinates wound care and detox referrals alongside medically supervised opioid use disorder treatment, addressing both the tissue damage and the dependence driving continued use. Ascend Recovery Center offers no-cost insurance verification and an ASAM Criteria evaluation to place each client at the right level of care, from PHP through IOP and outpatient telehealth. Contact Ascend Recovery Center at (561) 956-1082 to begin an assessment today.